Fund manager · Mirae

Tanmay Mehta

Fund Manager and research analyst at Mirae. Runs 1 scheme worth ₹3,494 Cr.

Fund house
MiraeThey run their schemes at Mirae.
AUM they run
₹3,494 CrThe AUM of the schemes they run, as main or co-manager, at the latest month's end, as AMFI reports it. A scheme two people run counts for both.
Schemes
1 now · 0 beforeSchemes they run now, as main or co-manager, and ones they ran before, since Apr 2025.
Experience
13 yearsMr. Tanmay Mehta has over 13 years of experience primarily into equity research. He has been associated with the AMC since Jan 2021. Prior to this, Mr. Mehta has worked across Institutional Equity Research and Investment Banking Functions at SBI Capital Markets. He is a Chartered Accountant and has also cleared CFA (US).

What Tanmay Mehta's schemes hold^{(Apr 2025 – Sept 2026)}

What Tanmay Mehta's schemes hold in Sept 2026. Tick up to 2 to plot them.
Plot	29 companies ·	₹ Cr
	Sun Pharmaceutical Ind Ltd	355
	Divi s Laboratories Limited	342
	Torrent Pharmaceuticals Limited	238
	Apollo Hospitals Enterprise Limited	196
	Laurus Labs Limited	193
	Dr Reddy s Laboratories Limited	169
	Glenmark Pharmaceuticals	167
	Aurobindo Pharma	132
	Alkem Laboratories Limited	131
	IPCA Laboratories Limited	118
	Krishna Institute of Medical Science Ltd	118
	Aster DM Healthcare Limited	116
	Sai Life Sciences Limited	113
	Onesource Speciality Pharma Ltd	105
	Fortis Healthcare Limited	103
	Dr Lal Path Labs Limited	101
	Gland Pharma Limited	93.9
	Cipla	92
	Eris Lifesciences Limited	83.4
	Max Healthcare Institute Limited	82
	Lupin	79.2
	Mankind Pharma Limited	78.4
	Biocon	70.1
	Molbio Diagnostics Limited	61.9
	Symbiotec Pharmalab Limited	55.8
	Neogen Chemicals Limited	52.5
	Anthem Biosciences Limited	32.5
	Deepak Nitrite Limited	14
	Narayana Hrudayalaya Limited	0.04

Sun Pharmaceutical Ind Ltd
Divi s Laboratories Limited

Market value of each ticked company across the schemes Tanmay Mehta runs, ₹ crore. Month end. Source: AMC monthly portfolio disclosures.
Month	Sun Pharmaceutical Ind Ltd	Divi s Laboratories Limited
Sept 2025	₹320 Cr	₹214 Cr
Oct 2025	₹339 Cr	₹250 Cr
Nov 2025	₹367 Cr	₹241 Cr
Dec 2025	₹345 Cr	₹238 Cr
Jan 2026	₹320 Cr	₹225 Cr
Feb 2026	₹335 Cr	₹232 Cr
Mar 2026	₹336 Cr	₹218 Cr
Apr 2026	₹346 Cr	₹242 Cr
May 2026	₹344 Cr	₹248 Cr
Jun 2026	₹356 Cr	₹245 Cr
Jul 2026	₹381 Cr	₹300 Cr
Aug 2026	₹387 Cr	₹352 Cr
Sept 2026	₹355 Cr	₹342 Cr

Fig. 1.Market value of each ticked company across the schemes Tanmay Mehta runs, ₹ crore. Month end. Source: AMC monthly portfolio disclosures.

Allocation^{(Sept 2026)}

Market cap

		% of AUM
Large Cap	5	34.99

Mid Cap	14	42.11

Small Cap	8	19.51

Unlisted	2	3.37

Sectors

Companies

Fig. 2.What the schemes this manager runs hold, all together, by market cap, by sector and by company. Hover a slice or a row; click a slice to open it.

What Tanmay Mehta bought and sold^{(Oct 2025 – Sept 2026)}

What Tanmay Mehta bought and sold. Change in market value since the previous month, ₹ crore. Month end. Source: AMC monthly portfolio disclosures.

Fig. 3.Change in market value since the previous month, ₹ crore. Month end. Source: AMC monthly portfolio disclosures.